Shots:

• Arrowhead to receive $120M up front and is eligible for $30M for P-II program & $100M upon achievement of P-II trial results, $190M as commercial milestone, $590M in sales-related milestone along with royalties on net product sales. The transaction is expected to close in Q1’22
• GSK to get an exclusive license to develop & commercialize ARO-HSD in all countries except Greater China & will be responsible for the clinical development & commercialization outside of Greater China
• ARO-HSD is being evaluated in the P-I/II trial to evaluate the safety, tolerability, PK & PD in ~74 normal healthy volunteers with NASH. Arrowhead also plans to start P-II & P-III studies for ARO-HSD

Ref: Arrowhead | Image: Arrowhead